The latest report by IMARC Group, titled “Gastric Cancer Drugs Market Report by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on the gastric cancer drugs market report.
What is the market size of gastric cancer drugs?
The global gastric cancer drugs market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.26% during 2024-2032.
Factors Affecting the Growth of the Gastric Cancer Drugs Industry:
- Increasing Clinical Trials:
The expanding pipeline of novel agents and ongoing clinical trials focused on gastric cancer treatment significantly drives the market forward. Pharmaceutical companies, academic institutions, and research organizations are actively investigating various therapeutic modalities, including immune checkpoint inhibitors, antibody-drug conjugates, and small molecule inhibitors, among others. As promising candidates progress through clinical development stages and receive regulatory approvals, they provide new treatment options for patients with advanced or metastatic gastric cancer, driving market growth and innovation in the field of gastric cancer drugs.
- Rising Prevalence of Gastric Cancer:
The rising incidence and prevalence of gastric cancer worldwide contribute to the growing demand for gastric cancer drugs. Factors such as aging populations, changes in lifestyle and dietary habits, and higher rates of Helicobacter pylori infection in certain regions contribute to the increasing burden of gastric cancer. This demographic trend drives pharmaceutical companies to invest in research and development for novel drugs and treatment approaches to address the unmet medical needs of gastric cancer patients.
- Government Initiatives and Funding:
Governments and healthcare organizations are increasingly recognizing the importance of addressing gastric cancer as a public health priority. Consequently, there has been a surge in initiatives aimed at raising awareness, promoting early detection and diagnosis, and improving access to treatment for gastric cancer patients. Government funding and support for research and development projects focused on gastric cancer drugs have also increased, fostering collaboration between academia, industry, and regulatory agencies to accelerate drug discovery and development processes. This support is driving innovation and investment in the gastric cancer drugs market, leading to the introduction of new therapeutic options for patients.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/gastric-cancer-drugs-market/requestsample
Competitive Landscape:
The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market.
- Abbott Laboratories
- Arog Pharamaceuticals Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Hoffmann-La Roche AG
- Ono Pharmaceutical Co. Ltd.
- Sanofi S.A.
- Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
Gastric Cancer Drugs Market Report Segmentation:
By Type:
- Doxorubicin Hydrochloride
- Sunitinib
- Docetaxel
- Mitomycin
- Fluorouracil
- Imatinib
- Trastuzumab
Trastuzumab holds the largest market share as it is highly effective in treating gastric cancer patients who overexpress human epidermal growth factor receptor 2 (HER2-positive).
By Route of Administration:
- Oral
- Parenteral
Parenteral dominate the market as it allows for more precise dosing and better absorption of therapeutic agents into the bloodstream, leading to enhanced efficacy.
By End User:
- Hospitals
- Clinics
- Others
Hospitals account for the largest market share as they offer comprehensive treatment facilities for gastric cancer patients, including diagnostic services, surgical procedures, chemotherapy, radiation therapy, and supportive care.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Asia Pacific’s dominance in the gastric cancer drugs market is attributed to the increasing healthcare expenditure, technological advancements, and rising geriatric population.
Global Gastric Cancer Drugs Market Trends:
Presently, immunotherapy has emerged as a promising treatment modality for gastric cancer, with the development of immune checkpoint inhibitors such as pembrolizumab and nivolumab. These drugs harness the body's immune system to target and destroy cancer cells, offering a novel therapeutic approach for patients with advanced or metastatic gastric cancer. The continued research and development in immunotherapy are driving innovation in the gastric cancer drugs market, with ongoing clinical trials evaluating combination therapies and novel immune targets. Besides, there is a growing emphasis on precision medicine in gastric cancer treatment, focusing on the identification of specific molecular alterations and biomarkers that can guide therapy selection. Biomarker testing, including HER2 amplification, PD-L1 expression, and microsatellite instability, is increasingly integrated into clinical practice to inform treatment decisions and personalize patient care.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=6648&flag=C
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
